RepliCel Life Sciences Inc (TSXV:RP)
RepliCel is a regenerative medicine company developing autologous cell therapies that address diseases caused by a deficit of healthy cells required for normal healing and function.
Denovo Biopharma, a San Diego-Hangzhou company, has started a pivotal Phase III trial of its lead drug, DB102 (enzastaurin). DB102, which was initially developed by Eli Lilly, failed a Phase III clinical trial in 2013 in patients with diffuse large B-cell lymphoma (DLBCL). Denovo acquired global rights to DB102 in 2014, planning to redevelop the drug by targeting a sub-set of patients. By analyzing Lilly’s patient samples, Denovo found overall survival was significantly improved for patients who possess the DGM1 biomarker. The study will enroll 235 patients in the US and China.
Source: China Biotoday
